You are leaving our website

or Decline

At a glance

Our 2021 Financial Highlights

Strong overall revenue growth driven by Consumer Healthcare, underpinned by continued market penetration via e-commerce activity, which now represents around 25% of Group sales

169.6 £m See-through Revenue*
42.2 £m Underlying Profit Before Tax
6.39p Underlying Basic EPS
163.2 £m Statutory Revenue
18.2 £m Reported Profit Before Tax

*Non-IFRS alternative performance measures. See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.

Results centre

2021 Annual Report

Annual Report

2021 Annual Report (7.6mb)


Working together to acheive more for investors

Our alliances, clear strategy and proven business model enable us to deliver consistent and sustained returns for investors.

Why Invest

Financial calendar

23Dec 2022 2022 Interim Dividend Record Date


Results centre